

REMARKS

Claims at 1-22 have been canceled. New Claims 23-57 have been added. New Claims 23-57 are directed to methods for the inhibition of angiogenesis in tumor formation or growth, for inhibiting metastasis of tumors and for reducing the recurrence of tumors. Support for new Claims 23-57 can be found generally throughout the specification, for example at Page 2, lines 18-26; Page 5, line 32 – page 6, line 7; Page 19, lines 25-28 and Examples I- III.


CONCLUSION

The Preliminary Amendment is accompanied by a check in the amount of \$117.00 to cover the fee for additional claims over those for which we had already been paid. No additional fees are believe due. However, the Director is hereby authorized to charge any deficiency, or credit any overpayment, to Deposit Account No. 11-0855.

Early and favorable consideration is earnestly solicited. If the Examiner believes any informalities remain in the application that may be corrected by Examiner's amendment, or there are any other issues that can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 532-6907 is earnestly solicited.

Respectfully submitted,

KILPATRICK STOCKTON, LLP



By: Jennifer R. Seng
Reg. No. 45,851

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, GA 30309-4530
Phone: (404) 815-6500
Fax: (404) 815-6555
KS File #: 42615-249244
Docket Number 03757-0406